# Dec 2018

Dr. Gannon Yu ASPIRES Physician Infectious Diseases **Dr. Jane Lin** ASPIRES Pharmacist PharmD, ACPR, BCPS Dr. Josh Douglas ASPIRES Physician Critical Care and Infectious Diseases

# **Coastal ASPIRES Antimicrobial Stewardship**

**Antimicrobial Stewardship** is...RIGHT **diagnosis**, RIGHT **drug**, RIGHT **dose**, RIGHT **route**, RIGHT **interval**, RIGHT **duration**!

### IN THIS ISSUE:

- Updated Coastal Antibiogram
- Moving Past the Routine Use of Macrolides for all patients with Community-Acquired Pneumonia

### **COASTAL SITE ENGAGEMENTS:**

- 01 Nov 2018 SGH Pharmacy
- 15 Jan 2019 Powell River Hospital
- 16 Jan 2019 Sechelt Hospital

# North Shore Infectious Diseases Clinic

Dr. Douglas & Dr. Yu

- **1** : 604-988-3494
- Fax: 604-988-6745
- Insinfectiousdiseases@gmail.com
- Discrete State and State a

#### 17th St W C 17th St E 16th S

# Question? Call 604-417-8921

Antimicrobial Stewardship Programme: Innovation, Research, Education, and Safety Quality and Patient Safety, Vancouver Coastal Health



Promoting wellness, Ensuring care

# **Dec 2018**

Antibiogram corrections on 18Sep2018 are reflected here.

#### Vancouver-CoastalHealth Medical Microbiology & Infection Control



### Antibiogram Jan - Dec 2017 Sea to Sky CoC



### **GRAM POSITIVE ORGANISMS**

methicillin-resistant M Staphylococcus lugdenensis S Staphylococcus epidermidis Viridans group Streptococcus Streptococcus pneumoniae S. pneumoniae (meningitis) S Streptococcus pyogenes (GAS) S Streptococcus agalactiae (GBS) S Enterococcus faecalis S	Staphylococcus aureus (all)	1
Staphylococcus lugdenensisStaphylococcus epidermidisStaphylococcus epidermidisViridans group StreptococcusStreptococcus pneumoniaeS. pneumoniae (meningitis)Streptococcus pyogenes (GAS)Streptococcus agalactiae (GBS)Enterococcus faecalisEnterococcus faecalis	methicillin-susceptible	N
Staphylococcus epidermidisViridans group StreptococcusStreptococcus pneumoniaeS. pneumoniae (meningitis)Streptococcus pyogenes (GAS)Streptococcus agalactiae (GBS)Enterococcus faecalisEnterococcus faecalis	methicillin-resistant	N
Viridans group StreptococcusStreptococcus pneumoniaeS. pneumoniae (meningitis)Streptococcus pyogenes (GAS)Streptococcus agalactiae (GBS)Enterococcus faecalisEnterococcus faecalis	Staphylococcus lugdenensis	1
Streptococcus pneumoniaeS. pneumoniae (meningitis)Streptococcus pyogenes (GAS)Streptococcus agalactiae (GBS)Enterococcus faecalisEnterococcus faecalis	Staphylococcus epidermidis	
S. pneumoniae (meningitis) Streptococcus pyogenes (GAS) Streptococcus agalactiae (GBS) Enterococcus faecalis Enterococcus faecium	Viridans group Streptococcus	-
Streptococcus pyogenes (GAS)Streptococcus agalactiae (GBS)Enterococcus faecalisEnterococcus faecium	Streptococcus pneumoniae	
Streptococcus agalactiae (GBS) Enterococcus faecalis Enterococcus faecium	S. pneumoniae (meningitis)	٧
Enterococcus faecalis Enterococcus faecium	Streptococcus pyogenes (GAS)	2
Enterococcus faecium	Streptococcus agalactiae (GBS)	1
	Enterococcus faecalis	5
vancomycin-susceptible v	Enterococcus faecium	1
	vancomycin-susceptible	v

ureus (all)	1386			83		98		82	97	76	100	
methicillin-susceptible	N/A			100		99		85	98	84	100	
methicillin-resistant	N/A			0		97		53	93	43	100	
Igdenensis	120			99		100		85	99	93	100	1
pidermidis	45			48		85		52	64	77	100	
reptococcus	91	94	94		100	76		86		99	100	
eumoniae	47	100	100		100	69	78			100	100	
neningitis)	VCH	83			100						100	
ogenes (GAS)	259	100	100		100	61	73	73		100	100	
alactiae (GBS)	158	100	100		100	25	57	61	2	97	100	
calis	505		100			******					99	55
cium	59		17								59	5
ancomycin-susceptible	VCH		19								100	1
vancomycin-resistant	VCH		0								0	0

\* penicillin predicts all beta lactams for streptococci += ampicillin predicts pipercillin and imipenem for enterococcus

‡ cefazolin predicts cloxacillin, pipercillin-tazobactam and carbapenems for staphylococci



#### GRAM NEGATIVE ORGANISMS

Escherichia coli Klebsiella pneumoniae Klebsiella oxytoca **Citrobacter species** Enterobacter aerogenes Enterobacter cloacae Proteus mirabilis Morganella morganii Serratia marcescens Pseudomonas aeruginosa Acinetobacter (all)

533	63	87	90	93		79	83	93	99	100	98
326	0	94	94	95	1	94	97	98	98	100	36
80	0	90	83	95		98	98	100	95	99	81
94	0	28	3	86		91	97	96	99	100	70
51	0	0	0	88		98	98	100	90	100	8
42	0	0	0	73		100	95	98	81	100	18
230	82	97	47	98		85	87	93	100	100	0
50	0	0	0	100		80	86	92	100	100	0
37	0	0	0	89		100	97	100	95	97	0
177	0	0	0	0	95		95	97	96	91	0
43	0	0	0	0	81	86	93	95	95	98	0

\*cefazolin predicts ceftriaxone if not reported

### Question? Call 604-417-8921

Antimicrobial Stewardship Programme: Innovation, Research, Education, and Safety Quality and Patient Safety, Vancouver Coastal Health



# Dec 2018

Azithromycin - Master of Lingering								
Oral Bioavailability/Absorption	Moderate (~40%)							
Dosing Regimen (for Atypical Pneumonia)	<ul> <li>A total treatment dose of 1.5g (PO/IV)</li> <li>500mg PO/IV daily x 3 days</li> <li>500mg PO/IV x 1 day, then 250mg PO x 4 days</li> </ul>							
Half-Life	68 to 72 hours							
Renal Dose Adjustment	No							



# Total dose of 1.5g equals 7 days of effective therapy!

### What:

- Incidence of atypical pneumonia is < 2 cases/10,000 adults in the community.<sup>1</sup>
- Combination of beta-lactam/macrolide therapy was recommended based on low-quality observational/retrospective studies.<sup>1</sup>

### So What:

• Recent randomized controlled trials have shown that **beta-lactam monotherapy** is not inferior to **combination of beta-lactam/macrolide therapy** for clinical outcomes such as 90-day mortality and length of stay in hospital.<sup>1,2,3</sup>

### Now What:

- Consider beta-lactam monotherapy (ie. Ceftriaxone IV or Cefuroxime PO/IV) for patients with mild-moderate (non-ICU) CAP
  - O Mild-Moderate: Pneumonia Severity Index (PSI) class I-III
  - O PSI Calculator: https://www.mdcalc.com/psi-port-score-pneumonia-severity-index-cap
- Limit azithromycin course to total of 1.5g
- 1. Current Infectious Disease Reports (2018) 20:45
- 2. N Engl J Med. 2015;372:1312
- 3. Respir Med. 2017;129:145-51

# Question? Call 604-417-8921

Antimicrobial Stewardship Programme: Innovation, Research, Education, and Safety Quality and Patient Safety, Vancouver Coastal Health



